Meilen, Switzerland

Veronica Gambillara Fonck

This inventor holds 8 USPTO granted patents and 2 published patent applications. Top assignees: Glaxosmithkline Biologicals Sa, Janssen Pharmaceuticals, Inc.. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Veronica Gambillara Fonck. Retrieved from https://idiyas.com/inventor/veronica-gambillara-fonck

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 8 

% Patents Active = 100.0

Average Co-Inventor Count = 11.8

ph-index = 2

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 2020-2026

Loading Chart...
8 patents (USPTO):Explore Patents

Title: **Innovations and Contributions of Veronica Gambillara Fonck**

Introduction

Veronica Gambillara Fonck is a notable inventor based in Meilen, Switzerland, recognized for her significant contributions to the field of bioconjugates and immunology. With a portfolio of seven patents, her work addresses critical health concerns and enhances the development of vaccines against extra-intestinal pathogenic infections.

Latest Patents

Among her latest innovations are two pivotal patents. The first patent outlines "Methods of producing bioconjugates of O-antigen polysaccharides, compositions thereof, and methods of use thereof." This invention focuses on methodologies for producing bioconjugates utilizing recombinant host cells that express specific oligosaccharyl transferase enzymes crucial for the synthesis of the desired bioconjugates. Notably, these enzymes include PglB oligosaccharyl transferase or its variants.

Her second patent, titled "Methods and compositions for immune protection against extra-intestinal pathogenic," describes innovative formulations and techniques intended to elicit an immune response against extra-intestinal pathogens (ExPEC). This patent details the use of conjugates formed from polysaccharide antigens O25B, O1A, O2, and O6A, which are covalently attached to a detoxified exotoxin A of the (EPA) carrier protein, serving as a vaccine to prevent invasive diseases caused by specific ExPEC serotypes.

Career Highlights

Veronica has worked with prominent organizations in the pharmaceutical industry, including GlaxoSmithKline Biologicals SA and Janssen Pharmaceuticals, Inc. Her experience in these leading companies has played a vital role in shaping her expertise and influence in innovative vaccine development.

Collaborations

Throughout her career, Veronica has collaborated with notable professionals, including Darren Robert Abbanat and Patricia Ibarra Yon. These collaborations have contributed to her research and the successful development of her innovative approaches in immunology.

Conclusion

Veronica Gambillara Fonck stands out as a pioneering inventor whose work in bioconjugates and immune response strategies has the potential to vastly improve health outcomes related to extra-intestinal pathogenic infections. Her patents not only enhance our understanding of complex immunological processes but also pave the way for the development of effective vaccines.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…